SHTDY (Sinopharm Group Co) Accounts Payable: $21,972 Mil (As of Dec. 2025)


SHTDY Sinopharm Group Co Ltd SHTDY
73 GF Score
Price $10.45
GF Value $13.04
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Accounts Payable?

Sinopharm Group Co SHTDY +2.87% 73 Accounts Payable is $21,972 Mil as of Dec. 2025. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.04 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co's Accounts Payable for the quarter that ended in Dec. 2025 was $21,972 Mil.

Sinopharm Group Co's quarterly Accounts Payable declined from Dec. 2024 ($21,546 Mil) to Jun. 2025 ($21,262 Mil) but then increased from Jun. 2025 ($21,262 Mil) to Dec. 2025 ($21,972 Mil).

Sinopharm Group Co's annual Accounts Payable declined from Dec. 2023 ($21,673 Mil) to Dec. 2024 ($21,546 Mil) but then increased from Dec. 2024 ($21,546 Mil) to Dec. 2025 ($21,972 Mil).

Sinopharm Group Co Accounts Payable Related Terms

Sinopharm Group Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Accounts Payable Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,860.51 20,743.39 21,672.70 21,545.97 21,971.57

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21,672.70 21,480.54 21,545.97 21,262.46 21,971.57
SHTDY
73GF Score
Sinopharm Group Co Ltd SHTDY
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $21,972 Mil mean?
Sinopharm Group Co (SHTDY) has a Accounts Payable of $21,972 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Accounts Payable too high?
Sinopharm Group Co's current Accounts Payable is $21,972 Mil. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Accounts Payable compare to MCK and CAH?
Sinopharm Group Co's Accounts Payable of $21,972 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Distribution company?
A good Accounts Payable depends on the Medical Distribution industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Accounts Payable is $21,972 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.04, compared to a current price of $10.45 — trading 19.8% below its estimated fair value. The current Accounts Payable is $21,972 Mil. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Accounts Payable is $21,972 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $10.45 is trading 19.8% below its estimated GF Value™ of $13.04. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Accounts Payable: $21,972 Mil
  • GF Value™: $13.04 vs. price of $10.45 (19.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score

Get the complete analysis for SHTDY

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.45
Price
$13.04
GF Value